Evidence map›Paper›PMID 33078077›Full record

ReviewNature reviews. Materials2020

A materials-science perspective on tackling COVID-19.

Zhongmin Tang, Na Kong, Xingcai Zhang, Yuan Liu, Ping Hu, Shan Mou, Peter Liljeström, Jianlin Shi, Weihong Tan, Jong Seung Kim and 5 more

Abstract readReview
In one paragraph

Review in Nature reviews. Materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed.

  1. Machine-Learning Microfluidic Minute-Scale Microorganism Metrics Monitoring(M6).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. More than just a delivery system.Nature reviews. Chemistry · 2026
    Article
  4. Article
  5. Article
  6. Multiscale Construction, Evaluation, and Application of Organoids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhongmin Tang *Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.ORCID 0000-0002-1532-8004
Na Kong *Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Xingcai Zhang *School of Engineering and Applied Sciences, Harvard University, Cambridge, MA USA.ORCID 0000-0001-7114-1095
Yuan LiuCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Ping HuState Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China.
Shan MouInstitute of Molecular Medicine (IMM), Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Peter LiljeströmDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Jianlin ShiState Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-8790-195X
Weihong TanInstitute of Molecular Medicine (IMM), Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-8066-1524
Jong Seung KimDepartment of Chemistry, Korea University, Seoul, Korea.
Yihai CaoDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Robert LangerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA USA.ORCID 0000-0003-4255-0492
Kam W LeongDepartment of Biomedical Engineering, Columbia University, New York, NY USA.
Omid C FarokhzadCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Wei TaoCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.ORCID 0000-0002-4277-3728

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing SARS-CoV-2 pandemic highlights the importance of materials science in providing tools and technologies for antiviral research and treatment development. In this Review, we discuss previous efforts in materials science in developing imaging systems and microfluidic devices for the in-depth and real-time investigation of viral structures and transmission, as well as material platforms for the detection of viruses and the delivery of antiviral drugs and vaccines. We highlight the contribution of materials science to the manufacturing of personal protective equipment and to the design of simple, accurate and low-cost virus-detection devices. We then investigate future possibilities of materials science in antiviral research and treatment development, examining the role of materials in antiviral-drug design, including the importance of synthetic material platforms for organoids and organs-on-a-chip, in drug delivery and vaccination, and for the production of medical equipment. Materials-science-based technologies not only contribute to the ongoing SARS-CoV-2 research efforts but can also provide platforms and tools for the understanding, protection, detection and treatment of future viral diseases.

Indexed as

DiseasesMaterials scienceNanoscience and technologyVirology

Identifiers

PMID33078077
PMCPMC7556605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.